Down regulated expression of claudin-1 and claudin-5 and up regulation of β-catenin: Association with human glioma progression

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 8, 2014, Pages 1413-1426

  Karnati, Hanuma K ^a   Panigrahi, Manas ^b   Shaik, Noor A ^c   Greig, Nigel H ^d   Bagadi, S Appala R ^e   Kamal, Mohammad A ^c   Kapalavayi, Nagaiah ^a  

^a Gland Pharma Limited   (India)

^b Krishna Institute of Medical Sciences   (India)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e SAFDARJUNG HOSPITAL CAMPUS   (India)

Author keywords

Adheren junction; Claudin 1 (CLDN1); Claudin 5 (CLDN5); Glioblastoma multiforme (GBM); Glioma; Tight junction (TJ); catenin

Indexed keywords

BETA CATENIN; CLAUDIN 1; CLAUDIN 5; RNA;

ARTICLE; BRAIN BIOPSY; CELL LYSATE; CELL VIABILITY ASSAY; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; PILOCYTIC ASTROCYTOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA EXTRACTION; TIGHT JUNCTION; TUMOR CLASSIFICATION; TUMOR GROWTH; WESTERN BLOTTING; BRAIN TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BETA CATENIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CLAUDIN-1; CLAUDIN-5; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS;

EID: 84925745147     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666141023121550     Document Type: Article

References (86)

1. Bertossi M, Virgintino D, Maiorano E, Occhiogrosso M, Roncali L. Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol 1997; 21(1): 41-9.
2. Dinda AK, Sarkar C, Roy S, et al. A transmission and scanning electron microscopic study of tumoral and peritumoral microblood vessels in human gliomas. J Neurooncol 1993; 16(2): 149-58.
3. Hirano A, Matsui T. Vascular structures in brain tumors. Hum Pathol 1975; 6(5): 611-21.
4. Rothstein JD. Paving new pathways. Nat Med 2002; 8: 938-40.
5. Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 2008; 105(2): 287-95.
6. Lee SG, Kim K, Kegelman TP, et al. AEG-1 promotes gliomainduced neurodegeneration by increasing glutamate excitotoxicity. Cancer Res 2011; 71(20): 6514-23.
7. Hadj-Rabia S, Baala L, Vabres P, et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology 2004; 127(5): 1386-90.
8. Paganelli M, Stephenne X, Gilis A, et al. Neonatal ichthyosis and sclerosing cholangitis syndrome: extremely variable liver disease severity from claudin-1 deficiency. J Pediatr Gastroenterol Nutr 2011; 53(3): 350-4.
9. Grosse B, Cassio D, Yousef N, et al. Claudin-1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability. Hepatology 2012; 55(4): 1249-59.
10. Uyguner O, Emiroglu M, Uzumcu A, et al. Frequencies of gap-and tight-junction mutations in Turkish families with autosomalrecessive non-syndromic hearing loss. Clin Genet 2003; 64(1): 65-9.
11. Lee K, Ansar M, Andrade PB, et al. Novel CLDN14 mutations in Pakistani families with autosomal recessive non-syndromic hearing loss. Am J Med Genet A 2012; 158(2): 315-21.
12. Charif M, Bakhchane A, Abidi O, et al. Analysis of CLDN14 gene in deaf Moroccan patients with non-syndromic hearing loss. Gene 2013; 523(1): 103-5.
13. Konard M, Hou J, Weber S, et al. CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2008; 19(1): 171-81.
14. Seeley HH, Loomba-Albrecht LA, Nagel M, Butani L, Bremer AA. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis in three siblings having the same genetic lesion but different clinical presentations. World J Pediatr 2012; 8(2): 177-80.
15. Furuse M, Sasaki H, Fujimoto K, Tsukita SH. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J Cell Biol 1998; 143: 391-401.
16. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita SH. Claudin-1 and -2: novel integral membrane proteines localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998; 141(7):1539-50.
17. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 1999; 96(2): 511-6.
18. Ramirez SH, Fan S, Dykstra H, et al. Inhibition of Glycogen Synthase Kinase 3b Promotes Tight Junction Stability in Brain Endothelial Cells by Half-Life Extension of Occludin and Claudin-5. PLoS ONE 2013; 8(2): e55972.
19. Morita K, Sasaki H, Fujimoto K, Furuse M, Tsukita S. Claudin-11/OSP-based tight junctions of myelin sheaths in brain and Sertoli cells in testis. J Cell Biol 1999; 145(3): 579-88.
20. Shang X, Lin X, Alvarez E, Manorek G, Howell SB. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia 2012; 14(10): 974-85.
21. Lafemina MJ, Sutherland KM, Bentley T, et al. Claudin-18 deficiency results in alveolar barrier dysfunction and impaired alveologenesis in mice. Am J Respir Cell Mol Biol 2014; 51(4): 550-8.
22. Karanjawala ZE, Illei PB, Ashfaq R, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 2008; 32(2): 188.
23. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Discovery of novel tumor markers of pancreatic canceusing global gene expression technology. Am J Pathol 2002; 160(4): 1239-49.
24. Izraely S, Sagi-Assif O, Klein A, et al. The Metastatic Microenvironment: Claudin-1 Suppresses the Malignant Phenotype of Melanoma Brain Metastasis. Int J Cancer 2014; Epub ahead of print].
25. Kramer F, White K, Kubbies M, Swisshelm K, Weber BH. Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum Genet 2000; 107(3): 249-56.
26. Szász AM, Nyirády P, Majoros A, et al. Beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU Int 2010; 105(5): 716-22.
27. Ding L, Lu Z, Lu Q, Chen YH. The claudin family of proteins in human malignancy: a clinical perspective. Cancer management and research 2013; 5: 367-75.
28. Kominsky SL, Argani P, Korz D, et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003; 22(13): 2021-33.
29. Sheehan GM, Kallakury BV, Sheehan CE, et al. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 2007; 38(4): 564-9.
30. Usami Y, Chiba H, Nakayama F, et al. Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol 2006; 37(5): 569-77.
31. Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 2000; 100(3): 323-31.
32. Roe K, Kumar M, Lum S, et al. West Nile virus-induced disruption of the blood-brain barrier in mice is characterized by the degradation of the junctional complex proteins and increase in multiple matrix metalloproteinases. J Gen Virol 2012; 93(Pt 6): 1193-203.
33. Feng S, Cen J, Huang Y, et al. Matrix Metalloproteinase-2 and -9 Secreted by Leukemic Cells Increase the Permeability of Blood Brain Barrier by Disrupting Tight Junction Proteins. PLoS ONE 2011; 6(8): e20599.
34. Gu YT, Xue YX, Wang YF, et al. Minoxidil sulfate induced the increase in blood–brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway. Neuropharmacology 2013; 75: 407-15.
35. D'Souza T, Agarwal R, Morin PJ. Phosphorylation of claudin-3 at threonine 192 by pka regulates tight junction barrier function in ovarian cancer cells. J Biol Chem 2005; 280(28): 26233-40.
36. Kominsky SL, Vali M, Korz D, et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 2004; 164(5): 1627-33.
37. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4in prostate cancer epithelium. Cancer Res 2001; 61(21): 7878-81.
38. Gress TM, Müller-Pillasch F, Geng M, et al. A pancreatic cancerspecific expression profile. Oncogene 1996; 13(8): 1819-30.
39. Terris B, Blaveri E, Crnogorac-Jurcevic T, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. AmJ Pathol 2002; 160(5): 1745-54.
40. Lee JW, Hsiao WT, Chen HY, et al. Upregulated claudin-1 expression confers resistance to cell death of nasopharyngeal carcinoma cells. Int J Cancer 2010; 126(6): 1353-66.
41. Blanchard AA, Ma X, Dueck KJ, et al. Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer 2013; 13: 268.
42. Huber JD, Witt KA, Hom S, et al. Inflammatory pain alters bloodbrain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2001; 280(3): H1241-8.
43. Sawada N, Murata M, Kikuchi K, et al. Tight junctions and human diseases. Med Electr Microsc 2003; 36(3): 147-56.
44. Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci Lett 2001; 307(2): 77-80.
45. Bronstein JM, Tiwari-Woodruff S, Buznikov AG, Stevens DB. Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: role in biology and disease. J Neurosci Res 2000; 59(6): 706-11.
46. Gumbiner B, Simons K. A functional assay for proteins involved in establishing an epithelial occluding barrier: identification of a uvomorulin-like polypeptide. J Cell Biol 1986; 102(2): 457-68.
47. Rodriguez-Boulan E, Nelson WJ. Morphogenesis of the polarized epithelial cell phenotype. Science 1989; 245(4919): 718-25.
48. Nelson WJ. Regulation of cell surface polarity from bacteria to mammals. Science 1992; 258(5084): 948-55.
49. Schulze C, Firth JA. Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat. J Cell Sci 1993; 104(Pt 3): 773-82.
50. Lampugnani MG, Corada M, Caveda L, et al. The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, β-catenin and a-catenin with vascular endothelial cadherin (VE-cadherin). J Cell Biol 1995; 129(1): 203-17.
51. Liebner S, Gerhardt H, Wolburg H. Differential expression of endothelial β-catenin and plakoglobin during development and maturation of the blood-brain and blood-retina barrier in the chicken. Dev Dyn 2000; 217(1): 86-98.
52. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995; 92(7): 3046-50.
53. Yost C, Torres M, Miller JR, et al. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10(12): 1443-54.
54. Behrens J, von Kries JP, Kühl M, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996; 382(6592): 638-42.
55. Fagotto F, Glück U, Gumbiner BM. Nuclear localization signalindependent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 1998; 8(4): 181-90.
56. Miller JR, Moon RT. Signal transduction through β-catenin and specification of cell fate during embryogenesis. Genes Dev 1996; 10(20): 2527-39.
57. Rutten MJ, Hoover RL, Karnovsky MJ. Electrical resistance and macromolecular permeability of brain endothelial monolayer cultures. Brain Res 1987; 425(2): 301-10.
58. Rakhade SN, Yao B, Ahmed S, et al. A common pattern of persistent gene activation in human neocortical epileptic foci. Ann Neurol 2005; 58(5): 736-47.
59. Abe T, Sugano E, Saigo Y, Tamai M. Interleukin-1β and Barrier Function of Retinal Pigment Epithelial Cells (ARPE-19): Aberrant Expression of Junctional Complex Molecules Invest. Ophthalmol. Vis Sci 2003; 44(9): 4097-104.
60. Shaik NA, Lone WG, Khan IA, et al. Enhanced transcription of estrogen receptor α and mitochondrial cytochrome b genes in uterine leiomyomas. Gynecol Endocrinol 2011; 27(12): 1094-8.
61. Kniesel U, Risau W, Wolburg H. Development of bloodbrain barrier tight junctions in the rat cortex. Dev Brain Res 1996; 96(1-2): 229-40.
62. Itoh M, Nagafuchi A, Yonemura S, et al. The 220 KD protein colocalizing with cadherins in non-epithelial cells is identical to ZO-1, a tight junction associated protein in epithelial cells – cDNA cloning and immunoelectron microscpy. J Cell Biol 1993; 121(3): 491-502.
63. Knudsen KA, Frankowski C, Johnson KR, Wheelock MJ. A role for cadherins in cellular signaling and differentiation. J Cell Biochem Suppl 1998; 30-31: 168-76.
64. Morita K, Sasaki H, Furuse M, Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 1999; 147(1): 185-94.
65. Greig NH. Brain tumors and the blood-tumor barrier, in Implications of the Blood-Brain Barrier and Its Manipulation: Vol. 2. Clinical Aspects (Neuwelt EA ed), Plenum Publishing Corp., New York, 1989; pp. 77-106.
66. Greig NH. Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987; 14: 1-28.
67. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: reality check. J Clin Oncol 2007; 25: 2295-305.
68. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006; 6: 186.
69. Ishihara H, Kubota H, Lindberg RL, et al. Endothelial Cell Barrier Impairment Induced by Glioblastomas and Transforming Growth Factor beta]2 Involves Matrix Metalloproteinases and Tight Junction Proteins. J Neuropathol Experim Neurol 2008; 67(5): 435-48.
70. Lopez-Ramirez MA, Wu D, Pryce G, et al. MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. FASEB J 2014; 28(6): 2551-65.
71. Fletcher NF, Wilson G, Murray J, et al. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 2012; 142: 634-43.
72. Pfeiffer F, Schafer J, Lyck R, et al. Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis. Acta Neuropathol 2011; 122: 601-14.
73. Hoevel T, Macek R, Swisshelm K, Kubbies M. Reexpression of the TJ protein claudin-1 induces apoptosis in breast tumor spheroids. Int J Cancer 2004; 108(3): 374-83.
74. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Bio 2001; 2(4): 285-93.
75. Morohashi S, Kusumi T, Sato F, et al. Decreased expression of claudin-1correlates with recurrence status in breast cancer. Int J Mol Med 2007; 20(2): 139-43.
76. Tzelepi VN, Tsamandas AC, Vlotinou HD, Vagianos CE, Scopa CD. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol 2008; 21(1): 22-30.
77. Higashi Y, Suzuki S, Sakaguchi T, et al. Loss of claudin-1expression correlates with malignancy of hepatocellular carcinoma. J Surg Res 2007; 139(1): 68-76.
78. Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T. Tight junction protein claudin-1enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 g2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 2006; 66(10): 5251-7.
79. Leotlela PD, Wade MS, Duray PH, et al. Claudin-1 over expression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 2007; 26(26): 3846-56.
80. Christofori G. New signals from the invasive front. Nature 2006; 441(7092): 444-50.
81. Blanco D, Vicent S, Elizegi E, et al. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis. Lab Invest 2004; 84(8): 999-1012.
82. Greig NH, Ries LG, Yancik R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 1990; 82(20): 1621-4.
83. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 2005; 104(12): 2798-806.
84. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol 2008; 64(6): 628-34.
85. Lukas RV, Nicholas MK. Update in the treatment of high-grade Gliomas. Neurol Clin 2013; 31(3): 847-67.
86. Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 2014; 9: 357-67.